Targeting persisters for tuberculosis control

Ying Zhang, Wing Wai Yew, Michael R. Barer

Research output: Contribution to journalArticle

Abstract

Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease. We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection. Results from recent studies implicate multiple pathways for persister formation, including energy production, the stringent response, global regulators, the trans-translation pathway, proteasomal protein degradation, toxin-antitoxin modules, and transporter or efflux mechanisms. A combination of specifically persister- targeted approaches, such as catching them when active and susceptible either by stimulating them to "wake up" or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB. Variations in levels of persister formation and in host genetics can play a role in the outcome of clinical treatment, and thus, these may entail personalized treatment regimens.

Original languageEnglish (US)
Pages (from-to)2223-2230
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Tuberculosis
Antitoxins
Drug Combinations
Combination Drug Therapy
Pharmaceutical Preparations
Immunotherapy
Proteolysis
Therapeutics
Anti-Bacterial Agents
Infection
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Targeting persisters for tuberculosis control. / Zhang, Ying; Yew, Wing Wai; Barer, Michael R.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 5, 05.2012, p. 2223-2230.

Research output: Contribution to journalArticle

Zhang, Ying ; Yew, Wing Wai ; Barer, Michael R. / Targeting persisters for tuberculosis control. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 5. pp. 2223-2230.
@article{01a5dcb801fb48528eb4c727c91824c9,
title = "Targeting persisters for tuberculosis control",
abstract = "Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease. We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection. Results from recent studies implicate multiple pathways for persister formation, including energy production, the stringent response, global regulators, the trans-translation pathway, proteasomal protein degradation, toxin-antitoxin modules, and transporter or efflux mechanisms. A combination of specifically persister- targeted approaches, such as catching them when active and susceptible either by stimulating them to {"}wake up{"} or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB. Variations in levels of persister formation and in host genetics can play a role in the outcome of clinical treatment, and thus, these may entail personalized treatment regimens.",
author = "Ying Zhang and Yew, {Wing Wai} and Barer, {Michael R.}",
year = "2012",
month = "5",
doi = "10.1128/AAC.06288-11",
language = "English (US)",
volume = "56",
pages = "2223--2230",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Targeting persisters for tuberculosis control

AU - Zhang, Ying

AU - Yew, Wing Wai

AU - Barer, Michael R.

PY - 2012/5

Y1 - 2012/5

N2 - Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease. We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection. Results from recent studies implicate multiple pathways for persister formation, including energy production, the stringent response, global regulators, the trans-translation pathway, proteasomal protein degradation, toxin-antitoxin modules, and transporter or efflux mechanisms. A combination of specifically persister- targeted approaches, such as catching them when active and susceptible either by stimulating them to "wake up" or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB. Variations in levels of persister formation and in host genetics can play a role in the outcome of clinical treatment, and thus, these may entail personalized treatment regimens.

AB - Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease. We suggest that persisters in TB are heterogeneous in nature and comprise various proportions of the population depending on the circumstances; the mechanisms of their formation are complex and may be related to those required for persistence in chronic infection. Results from recent studies implicate multiple pathways for persister formation, including energy production, the stringent response, global regulators, the trans-translation pathway, proteasomal protein degradation, toxin-antitoxin modules, and transporter or efflux mechanisms. A combination of specifically persister- targeted approaches, such as catching them when active and susceptible either by stimulating them to "wake up" or by intermittent drug dosing, the development of new drugs, the use of appropriate drug combinations, and combined chemotherapy and immunotherapy, may be needed for more effective elimination of persisters and better treatment of TB. Variations in levels of persister formation and in host genetics can play a role in the outcome of clinical treatment, and thus, these may entail personalized treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=84860211277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860211277&partnerID=8YFLogxK

U2 - 10.1128/AAC.06288-11

DO - 10.1128/AAC.06288-11

M3 - Article

C2 - 22391538

AN - SCOPUS:84860211277

VL - 56

SP - 2223

EP - 2230

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -